tiprankstipranks
Hydreight Technologies Inc (TSE:NURS)
:NURS
NURS
Hydreight Technologies Inc
RESEARCH TOOLSreports

Hydreight Technologies Inc (NURS) Price & Analysis

37 Followers

NURS Stock Chart & Stats

C$3.98
--
Market closed
C$3.98
--
Day’s Range― - ―
52-Week RangeC$1.63 - C$5.59
Previous CloseN/A
VolumeN/A
Average Volume (3M)151.18K
Market Cap
C$228.38M
Enterprise ValueC$75.16M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)50.8
Beta1.01
Next Earnings
Sep 01, 2026
EPS Estimate
0.05
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,672,930
10 Day Avg. Volume81,450
30 Day Avg. Volume151,176
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$9.50
Price Target Upside138.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.29
Revenue Forecast (FY)C$149.91M

Hydreight Technologies Inc News

Hydreight Earns Buy Rating on Explosive Growth, Scalable Platform, and Attractive Valuation vs. 12-Month EBITDA-Based Target
Hydreight Earns Buy Rating on Explosive Growth, Scalable Platform, and Attractive Valuation vs. 12-Month EBITDA-Based Target
Analyst Allen Klee of Maxim Group reiterated a Buy rating on Hydreight Technologies Inc, with a price target...
24d ago
Hydreight Takes Stake in Insu Therapeutics to Back Needle-Free Peptide Delivery
Hydreight Takes Stake in Insu Therapeutics to Back Needle-Free Peptide Delivery
An announcement from Hydreight Technologies Inc ( ($TSE:NURS) ) is now available. Hydreight Technologies Inc. has made a...
4M ago
Hydreight Technologies: Strong 2026 Growth Guidance, Operating Leverage, and Discounted Valuation Support Buy Rating
Hydreight Technologies: Strong 2026 Growth Guidance, Operating Leverage, and Discounted Valuation Support Buy Rating
Analyst Allen Klee from Maxim Group reiterated a Buy rating on Hydreight Technologies Inc and increased the price...
5M ago
Hydreight Sets $150 Million Baseline Revenue Target for 2026, Signals Margin Expansion
Hydreight Sets $150 Million Baseline Revenue Target for 2026, Signals Margin Expansion
Hydreight Technologies Inc ( ($TSE:NURS) ) just unveiled an update. Hydreight Technologies has issued baseline fiscal 2026 revenue...
5M ago
Hydreight Technologies sees FY26 revenue $150M
Hydreight Technologies sees FY26 revenue $150M
The company said, “Based on current internal planning assumptions, the Company expects fiscal 2026 revenue of approximately $150M,...
5M ago
Hydreight Technologies sees Q1 revenue $25M-$28M
Hydreight Technologies sees Q1 revenue $25M-$28M
The company said, “The Company expects revenue to increase throughout fiscal 2026 as several major partnerships, clients, and...
5M ago
Hydreight Raises $15 Million in Oversubscribed Bought-Deal to Accelerate U.S. Digital Health Expansion
Hydreight Raises $15 Million in Oversubscribed Bought-Deal to Accelerate U.S. Digital Health Expansion
Hydreight Technologies Inc ( ($TSE:NURS) ) has shared an announcement. Hydreight Technologies Inc. has closed an oversubscribed bought-deal...
5M ago
Hydreight Raises C$10 Million in Bought Deal to Accelerate U.S. Digital Healthcare Growth
Hydreight Raises C$10 Million in Bought Deal to Accelerate U.S. Digital Healthcare Growth
Hydreight Technologies Inc ( ($TSE:NURS) ) has shared an announcement. Hydreight Technologies Inc. has launched a C$10 million...
6M ago
Hydreight Moves Into At-Home STI Testing With Exclusive Deal and 50,000 Pre-Orders
Hydreight Moves Into At-Home STI Testing With Exclusive Deal and 50,000 Pre-Orders
Hydreight Technologies Inc ( ($TSE:NURS) ) has shared an announcement. Hydreight Technologies has entered the at-home sexually transmitted...
6M ago
Hydreight enters distribution agreement with Health Screen Collective
Hydreight enters distribution agreement with Health Screen Collective
Hydreight Technologies (HYDTF) announced its entry into the rapidly expanding at-home sexually transmitted infection pre-screening market through an...
6M ago
Hydreight Beats 2025 Targets With 1.3 Million Orders and Rapid License Growth
Hydreight Beats 2025 Targets With 1.3 Million Orders and Rapid License Growth
An update from Hydreight Technologies Inc ( ($TSE:NURS) ) is now available. Hydreight Technologies has surpassed 1.3 million...
6M ago
Hydreight Technologies exceeds 1.3M product orders placed
Hydreight Technologies exceeds 1.3M product orders placed
Hydreight Technologies (HYDTF) provides an update on the Company’s recent operational performance and platform activity. Operational Highlights: Exceeded...
6M ago
Hydreight Technologies announces update highlighting Q3 momentum
Hydreight Technologies announces update highlighting Q3 momentum
On November 26, 2025, Hydreight reported its Q3 2025 financial and operational results in a release titled “Hydreight...
7M ago
Hydreight Technologies says 295,000 VSDHOne orders placed in Q3
Hydreight Technologies says 295,000 VSDHOne orders placed in Q3
For Q3 2025, VSDHOne recorded: about 295,000 product orders placed. As of December 1, 2025: approx. 887,000 total...
7M ago

NURS FAQ

What was Hydreight Technologies Inc’s price range in the past 12 months?
Hydreight Technologies Inc lowest stock price was C$1.63 and its highest was C$5.59 in the past 12 months.
    What is Hydreight Technologies Inc’s market cap?
    Hydreight Technologies Inc’s market cap is C$228.38M.
      When is Hydreight Technologies Inc’s upcoming earnings report date?
      Hydreight Technologies Inc’s upcoming earnings report date is Sep 01, 2026 which is in 63 days.
        How were Hydreight Technologies Inc’s earnings last quarter?
        Currently, no data Available
        Is Hydreight Technologies Inc overvalued?
        According to Wall Street analysts Hydreight Technologies Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Hydreight Technologies Inc pay dividends?
          Hydreight Technologies Inc does not currently pay dividends.
          What is Hydreight Technologies Inc’s EPS estimate?
          Hydreight Technologies Inc’s EPS estimate is 0.05.
            How many shares outstanding does Hydreight Technologies Inc have?
            Hydreight Technologies Inc has 53,672,930 shares outstanding.
              What happened to Hydreight Technologies Inc’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Hydreight Technologies Inc?
              Currently, no hedge funds are holding shares in TSE:NURS
              What is the TipRanks Smart Score and how is it calculated?
              Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                Hydreight Technologies Inc Stock Smart Score

                6
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Analyst Consensus

                Moderate Buy
                Average Price Target:
                C$9.50 (138.69% Upside)

                Blogger Sentiment

                Bullish
                TSE:NURS Sentiment 100%
                Sector Average ―

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                748.97%
                12-Months-Change

                Fundamentals

                Return on Equity
                21.54%
                Trailing 12-Months
                Asset Growth
                528.16%
                Trailing 12-Months
                Top Smart Score Stocks >

                Company Description

                Hydreight Technologies Inc

                Hydreight Technologies Inc provides health & wellness services. It offers a completely compliant turnkey business model for health professionals to offer fully licensed medical & health services. Its services include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments at a location of the customer's choice.

                Hydreight Technologies Inc (NURS) Earnings & Revenues

                Historic Earnings Reports

                NURS Stock 12 Month Forecast

                Average Price Target

                C$9.50
                ▲(138.69% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","5":"C$5","10":"C$10","2.5":"C$2.5","7.5":"C$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$9.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$9.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$9.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.73,5.096923076923077,5.463846153846154,5.830769230769231,6.197692307692308,6.564615384615385,6.931538461538462,7.298461538461539,7.665384615384616,8.032307692307693,8.399230769230769,8.766153846153847,9.133076923076924,{"y":9.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.73,5.096923076923077,5.463846153846154,5.830769230769231,6.197692307692308,6.564615384615385,6.931538461538462,7.298461538461539,7.665384615384616,8.032307692307693,8.399230769230769,8.766153846153847,9.133076923076924,{"y":9.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.73,5.096923076923077,5.463846153846154,5.830769230769231,6.197692307692308,6.564615384615385,6.931538461538462,7.298461538461539,7.665384615384616,8.032307692307693,8.399230769230769,8.766153846153847,9.133076923076924,{"y":9.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.9,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.73,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.73,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Detailed Analyst Forecast >

                Technical Analysis

                Overall Consensus
                Buy
                12Bullish
                6Neutral
                4Bearish
                Bullish
                Neutral
                Bearish
                Overall Consensus
                12
                6
                4
                Technical Analysis
                3
                6
                1
                Moving Averages
                9
                0
                3
                Technical Analysis >
                Similar Stocks
                Company
                Price & Change
                Follow
                EKG
                Cardiocomm Solutions
                ―
                ―
                RHT.H
                Reliq Health Technologies
                ―
                ―
                AIDX
                HEALWELL AI
                ―
                ―
                KOVO
                Kovo HealthTech Corporation
                ―
                ―
                CSPN
                CareSpan Health
                ―
                ―
                Compare TSE:NURS Stocks >

                Options Prices

                Currently, No data available
                ---
                Popular Stocks